The tumor-suppressor p53 provides a critical brake on tumor development. HDM2 (human double-minute 2), a p53 E3 ubiquitin ligase, is the principal cellular antagonist of p53. Mounting evidence has suggested that ribosomal proteins (RPs) modulate HDM2-p53 as a novel pathway for regulating p53 signaling. However, the upstream regulators that mediate RP-HDM2-p53 circuits remain poorly understood. Here we identify human coilin-interacting nuclear ATPase protein (hCINAP) as an interacting partner of ribosomal protein S14 (RPS14). RPS14 stabilized and activated p53 by inhibiting HDM2-mediated p53 polyubiquitination and degradation. More importantly, RPS14 was specifically modified with NEDD8 and hCINAP inhibited RPS14 NEDDylation by recruiting NEDD8-specific protease 1. The decrease in RPS14 NEDDylation led to reduced stability and incorrect localization of RPS14, thereby attenuating the interaction between RPS14 and HDM2. Free HDM2 stimulated p53 polyubiquitination and degradation.
INTRODUCTION
The tumor-suppressor protein p53, the 'guardian of the genome', is activated in response to a range of physiological stresses, such as genotoxic damage, oncogene activation, chemical insult and ribosomal stress.
1,2 HDM2 (human doubleminute 2), a p53 E3 ubiquitin ligase, acts as the principal cellular antagonist of p53 by promoting p53 polyubiquitination and degradation. 3 Many cellular stresses stabilize p53 by blocking the HDM2-p53 feedback loop. A recently identified ribosomal protein (RP)-HDM2-p53 signaling pathway is activated through several RPs that bind to HDM2 and block HDM2-mediated p53 ubiquitination and degradation, and this pathway appears to be a critical mediator of ribosomopathies and cancer. [4] [5] [6] [7] Although several RPs were found to stabilize and activate p53 by binding directly to the central acidic domain of HDM2 to inhibit E3 ligase activity on p53. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It is less certain whether there are some proteins that are involved in regulating the interaction between RPs and HDM2, and the upstream regulators that mediate RP-HDM2-p53 circuits remain poorly understood.
Ubiquitin-like modification of RPs is also involved in the p53 signaling pathway. Proteomic analysis identified a subset of RPs that are potential substrates for the ubiquitin-like molecule NEDD8. 18 Among these proteins, only ribosomal protein L11 (RPL11) has been further studied to understand the function of NEDDylation. NEDD8 controls the stability and subcellular localization of RPL11 and regulates nucleolar signaling by RPL11 to p53. 19 It remains to be seen whether other RPs can be modified by NEDD8 and whether there are some proteins that regulate the NEDDylation of RPs as a means of regulating RP-HDM2-p53 pathways.
Human coilin-interacting nuclear ATPase protein (hCINAP, also called adenylate kinase 6; UniProtKB/Swiss-Prot: Q9Y3D8) is highly conserved and ubiquitously expressed in different organisms. [20] [21] [22] Fap7, the yeast homolog of hCINAP, is an essential gene for yeast growth, and complete loss of Fap7 is lethal. 23 Conditional depletion of Fap7 causes defects in maturation of 18S rRNA and in assembly of the 40S subunit, whereas overexpression of Fap7 confers resistance to arsenate, a known toxin and carcinogen. 22, 24 hCINAP is essential for formation of Cajal bodies, 25, 26 which are multifunctional and dynamic subnuclear organelles involved in small nuclear RNA gene transcription and final maturation of small nuclear ribonucleoproteins and small nucleolar ribonucleoproteins. Additionally, specific transcriptional inhibition of RNA polymerase II by actinomycin D causes hCINAP to become sequestered in perinuclear caps. 27 Based on these data, it seems likely that hCINAP is a pivotal gene in human.
Here we identify RPS14 as a partner of hCINAP. We demonstrate that RPS14 stabilizes and activates p53 through binding to HDM2, and hCINAP inhibits this process through regulating the interaction between RPS14 and HDM2 by controlling the NEDDylation of RPS14. Collectively, our findings support the designation of hCINAP as a key regulator of RP-HDM2-p53 signaling, expand our understanding of the biological functions of hCINAP and define a novel regulator of p53.
RESULTS

RPS14 acts as a partner of hCINAP
To elucidate the function of hCINAP, we performed immunoprecipitation assays on HEK 293T cell extracts using anti-hCINAP and identified the hCINAP-associated proteins by mass spectrometry.
Five specific bands were observed specifically in anti-hCINAP immunoprecipitates as compared with control immunoglobulin G immunoprecipitates ( Figure 1a) . Mass spectrometry analysis revealed that some RPs were identified in anti-hCINAP immunoprecipitates. Peptides and proteins identified were shown in Supplementary Table S1 . Among them, ribosomal protein S14 (RPS14) was identified as a target protein. RPS14 was a key gene for human 5q
À syndrome and demonstrated to be involved in 18S rRNA maturation and 40S subunit assembly, 28 we therefore selected RPS14 for further study.
The interaction between hCINAP and RPS14 was confirmed by both in vitro and in vivo assays (Figures 1b and c) . FLAG-tagged hCINAP and hemagglutinin (HA)-tagged RPS14 were cotransfected into HEK 293T cells and examined by co-immunoprecipitation. RPS14 was specifically immunoprecipitated with hCINAP using anti-FLAG, and hCINAP was specifically immunoprecipitated with RPS14 using anti-HA (Figure 1b) . The direct physical interaction between hCINAP and RPS14 was also demonstrated by in vitro pull-down assay (Figure 1c) . Furthermore, the association of endogenous hCINAP with RPS14 was confirmed in HCT116 cells by co-immunoprecipitation using anti-hCINAP (Figure 1d ). These results demonstrate that hCINAP interacts directly with RPS14 in vivo and in vitro.
RPS14 stabilizes and activates p53 by binding to HDM2 and decreasing the HDM2-p53 interaction In addition to the essential functions of RPs in facilitating ribosome biogenesis and ensuring protein synthesis, recent studies have identified extra-ribosomal functions of RPs. 29 A number of RPs with well-established extra-ribosomal functions also inhibit the E3 ligase activity of HDM2 by binding to its central acidic domain. 30 Here we demonstrated that RPS14 stabilized and activated p53 by attenuating the effect of HDM2 (Figure 2a) . Moreover, upregulation of p53 protein level and activity by RPS14 occurred in a dose-dependent manner (Figure 2a) . Similarly, the level of endogenous p53 in HCT116 cells was increased after augmentation of RPS14 expression (Supplementary Figure S1) .
Our results showed that RPS14 enhanced p53 stability and activity by overcoming HDM2-mediated suppression. We thus wondered whether RPS14 also bound to HDM2 and inhibited its E3 ligase activity, thereby affecting p53 polyubiquitination and degradation. To test this hypothesis, an intense interaction between exogenous RPS14 and HDM2 was first confirmed by co-immunoprecipitation (Figure 2b ). The interaction of endogenous RPS14 and HDM2 was also identified by using extracts from HCT116 cells (Figure 2c) . Mapping of the binding region revealed that RPS14 intensely bound to the residues 145-347 containing central acidic domain of HDM2 ( Supplementary Figures S2a and b) . Moreover, overexpression of RPS14 led to a decrease in the interaction of HDM2 and p53 (Figure 2d ), which indicates that RPS14 stabilizes and activates p53 by preventing the interaction of HDM2 with p53. Furthermore, in vivo ubiquitination assays showed that RPS14 overexpression inhibited HDM2-mediated p53 polyubiquitination (Figure 2e , lane 4 vs lane 3), which is consistent with the observation that RPS14 upregulated p53 stability and activity (Figure 2a ). These results demonstrate that RPS14 is a member of the class of RPs that can bind HDM2 and inhibit HDM2-mediated p53 polyubiquitination. Furthermore, we found that RPS14 not only stabilized p53 but also stabilized HDM2 (Figures 2a and 3a) in a dose-dependent manner (Supplementary Figure S2c) . Because HDM2 was expressed from the exogenous pCMV-HDM2 plasmid, which lacks a p53 transcription binding site, it is unlikely that increased HDM2 resulted from p53 activation. We investigated whether RPS14 stabilized HDM2 by inhibiting auto-ubiquitination. Indeed, overexpression of RPS14 resulted in a decrease in HDM2 auto-ubiquitination (Figure 2f ), indicating that stabilization of HDM2 by RPS14 was most likely correlated to its inhibition of HDM2 auto-ubiquitination.
Recently, it was found that deficiency or haploinsufficiency of RPS14 caused activation of p53 and erythroid progenitor cell apoptosis. 31, 32 Zhou et al. 8 also showed that overexpression or depletion of RPS14 could activate p53 in HCT116 or A549 cell lines. Our results above showed that overexpression of RPS14 markedly induced p53 expression. We also analyzed whether short hairpin RNA (shRNA)-mediated RPS14 depletion activated p53 expression. The result showed that p53 expression was elevated in RPS14 shRNA-treated cells, while in ActD-treated cells, the reduction of RPS14 by RPS14 shRNA partially decreased the level of p53 induced by ActD (Supplementary Figure S3a) . The inhibition of ActD-induced p53 activity by depleting RPS14 may be explained by the following two reasons: one is through impairment of the RPS14-HDM2-p53 pathway and the other is due to general inhibition of global translation, which is supported by the work reported by Fumagalli et al. 33 These observations are consistent with those obtained by Zhou et al. 8 Our results together with that of Lu's group demonstrate that depletion of RPS14 activates p53, and RPS14 is also partially required for the ribosomal stressinduced p53 activation.
hCINAP inhibits RPS14-mediated p53 stability and activity by attenuating the interaction between RPS14 and HDM2 Having shown that hCINAP interacted with RPS14 both in vivo and in vitro, we next examined whether hCINAP was involved in the RPS14-HDM2-p53 pathway. We found that overexpression of hCINAP slightly decreased the stability and activity of p53 in a dose-dependent pattern (Supplementary Figure S4a) . Furthermore, we found that hCINAP overexpression markedly inhibited RPS14-mediated p53 stability and activity ( Figure 3a , lane 6 vs lane 4). To confirm the effect of hCINAP on p53 signaling is dependent on RPS14, we examined the effect of hCINAP on p53 in RPS14-depleted cells. Our results showed that overexpression of hCINAP decreased the level of p53, while in RPS14-depleted cells, the inhibition of p53 by hCINAP was abolished (Supplementary Figure  S4b) . However, neither HDM2 nor p53 was detected in antihCINAP immunoprecipitates (data not shown). Therefore, we tested the effect of hCINAP expression on the interaction between RPS14 and HDM2. Overexpression of hCINAP attenuated the RPS14-HDM2 interaction, whereas depletion of hCINAP enhanced this interaction (Figure 3b ). In vivo ubiquitination assays showed that overexpression of RPS14 inhibited HDM2-mediated p53 polyubiquitination (Figure 3c To demonstrate the effect of endogenous hCINAP on the stability and activity of p53, we used the lentivirus-hCINAP-shRNA to knockdown endogenous hCINAP expression. To verify that the effects of RNAi are specific, we introduced silent mutations His-ubiquitinated species were purified on Ni 2 þ -NTA agarose and analyzed by IB using monoclonal anti-p53 or anti-HDM2.
hCINAP regulates RP-HDM2-p53 pathway J Zhang et al (hCINAP mutants 1 and 2) in the shRNA sequence targeting hCINAP expression. As shown in Supplementary Figure S4c , the mRNA and protein expression levels of endogenous hCINAP were obviously reduced in hCINAP shRNA-treated cells (left panel). Furthermore, hCINAP shRNA-treated cells were transfected with wild-type Flag-hCINAP or RNAi-resistant Flag-hCINAP mutants 1 or 2. The result showed that overexpressed wild-type Flag-hCINAP was significantly depleted, whereas overexpressed RNAi-resistant Flag-hCINAP mutants 1 or 2 could not be depleted (Supplementary Figure S4c , right panel). These data indicate that the RNAi targeting hCINAP was specific and efficient. Under these conditions, we examined the effect of knockdown of endogenous hCINAP on the stability and activity of p53. As shown in Figure 3d and Supplementary Figure S4d , knock down of hCINAP increased the stability and activity of p53. Consistently, hCINAP deficiency attenuated the HDM2-medidated p53 polyubiqutination (Figure 3e ). These results demonstrate that hCINAP was an essential regulator of the RPS14-HDM2-p53 pathway and acted by affecting the interaction between RPS14 and HDM2.
RPS14 is specifically modified with NEDD8, and HDM2 is an E3 ligase for RPS14 NEDDylation Treatment with a low concentration of actinomycin D specifically reduces NEDDylation of RPL11 and causes relocalization of RPL11 from the nucleolus to the nucleoplasm, where RPL11 binds to HDM2 and inhibits HDM2-mediated p53 degradation. 19 Thus, we next set out to determine whether RPS14 is also modified with NEDD8 and, if so, to assess the function of RPS14 NEDDylation.
RPS14 was specifically modified with NEDD8 as shown by in vivo NEDDylation assays (Figures 4a, b and c) . HCT116 cells were transfected with plasmids expressing HA-RPS14 and His-NEDD8. Cells were lysed under highly denaturing conditions, and His-NEDDylated species were purified with Ni 2 þ -agarose beads and analyzed by immunoblotting using anti-HA. Several distinct bands corresponding to monoNEDDylated (28 kD) and polyNEDDylated RPS14 were detected (Figure 4a ). Consistent with this result for overexpressed RPS14, we found that endogenous RPS14 was also specifically modified with NEDD8 (Figures 4b and c) . Furthermore, HDM2 was demonstrated to act as an E3 ligase in the NEDDylation of RPS14 (Figures 4d and e) . Wild-type HDM2 promoted NEDDylation of RPS14 (Figure 4d, lane 4 vs lane 3) , whereas two mutants that lack E3 ligase activity, HDM2(C464A) and HDM2(1-437), 34 alleviated RPS14 NEDDylation (Figure 4e ). We also investigated ubiquitination of RPS14 by a His pull-down experiment, and the result showed that RPS14 was not ubiquitinated (Figure 4f ). These data suggest that RPS14 was specially modified with NEDD8 and that this process was facilitated by HDM2. hCINAP regulates RP-HDM2-p53 pathway J Zhang et al specific proteases are cysteine proteases that share common features at the active site, including a Cys-His-Asp triad, although their overall structures or sequences are quite different. 35 To identify whether hCINAP is a NEDD8-specific protease, we analyzed the three-dimensional structure and amino-acid sequence of hCINAP. We found three cysteines (Cys53, Cys81 and Cys122) that are similar to the cysteine in the Cys-His-Asp triad. Mutational analysis of these residues to alanine (Cys53Ala, Cys81Ala and Cys122Ala), however, revealed no obvious difference in RPS14 NEDDylation when compared with wild-type hCINAP (Supplementary Figure S5) . This result suggests that hCINAP is not a deNEDDylase and may function instead by recruiting a NEDD8-specific protease. To test this hypothesis, a highly specific deNEDDylating enzyme, NEDP1, was investigated. Overexpression of NEDP1 or hCINAP alone was capable of reducing RPS14 NEDDylation, and co-expression of NEDP1 and hCINAP resulted in an almost complete loss of RPS14 NEDDylation (Figure 5b ), indicating that hCINAP and NEDP1 function cooperatively in RPS14 deNEDDylation. Next, we performed co-immunoprecipitation to analyze the interaction of RPS14 with NEDP1 in the presence and absence of hCINAP. An interaction between RPS14 and NEDP1 was detected only in the presence, and not in the absence, of hCINAP (Figure 5c ). In addition, to investigate the relevance of RPS14 NEDDylation to p53 stability, we examined the p53 levels in HCT116 cells with depleted NEDP1 or depleted hCINAP. The results showed that depletion of NEDP1 or hCINAP increased p53 level, which suggests that hCINAP regulates p53 level through regulating RPS14 NEDDylation (Supplementary Figure S3b) . Taken together, these data indicate that RPS14 was specifically covalently modified with NEDD8 and that hCINAP inhibited RPS14 NEDDylation by recruiting the deNEDDylating enzyme NEDP1.
Inhibition of RPS14 NEDDylation by hCINAP causes incorrect localization and instability of RPS14
To gain insight into the biological function of RPS14 deNEDDylation, we first assessed the effect of deNEDDylation on the subcellular localization of RPS14 by immunofluorescence. Control cells had RPS14 localized in both the nucleolus and the cytoplasm (Figure 6a , top row), whereas cells transfected with hCINAP lacked nucleolar RPS14 (Figure 6a , second row). To determine whether this change in RPS14 localization resulted from deNEDDylation of RPS14, we examined RPS14 localization in NEDP1-transfected cells. Similar to overexpression of hCINAP, overexpression of NEDP1 also resulted in the disappearance of nucleolar RPS14 (Figure 6a , bottom row). By contrast, in hCINAP-depleted cells, RPS14 immunolabeling was increased throughout the cell, especially in the nucleolus (Figure 6a, third row) . hCINAP-depleted cells also had speckles of RPS14 signals in the nucleoplasm as indicated with arrows ( Figure 6a, third row) .
Next, we examined whether loss of NEDDylation and incorrect localization of RPS14 affected its stability. Protein levels of both overexpressed and endogenous RPS14 showed a gradual 6b and c) . To verify that the increased instability of RPS14 was due to a decrease in NEDDylation, we measured the half-life of RPS14 in the presence of cycloheximide, a protein synthesis inhibitor. Overexpression of either hCINAP or NEDP1 decreased the half-life of RPS14 in the absence of protein synthesis (Figure 6d ), indicating that the decrease in RPS14 expression was due to increased degradation of the protein. These data indicate that hCINAP regulated the subcellular localization and stability of RPS14 by inhibiting NEDDylation.
To investigate whether overexpression of hCINAP and NEDP1 affected ribosome biogenesis and nucleolar disruption, we tested the ribosome biogenesis in HeLa cells transfected either with hCINAP or NEDP1 by sucrose gradient analysis and examined the nucleolus localization of fibrillarin, a nucleolar marker, by immunofluorescence analysis. The results showed that overexpression of hCINAP or NEDP1 caused no impairment of ribosome biogenesis (Supplementary Figure S6a) , suggesting that the effect of hCINAP on p53 activity is through regulating RPS14-MDM2 (the mouse homolog of HDM2) interaction but not via decreasing ribosome biogenesis. The results of immunofluorescence analysis showed that overexpresssion of hCINAP or/and NEDP1 did not affect the nucleolus localization of fibrillarin (Supplementary Figure S6b) , indicating that hCINAP or/ and NEDP1 do not cause nucleolar disruption.
DISCUSSION
The tumor-suppressor protein p53 provides a critical brake in tumor development, and several pathways have been demonstrated to stabilize and activate p53. 2, 36 Notably, increasing evidence suggests that RP-HDM2-p53 pathways are a novel mechanism for regulating p53 signaling. 4, 7, 30, 37 Although some RPs are involved in this pathway, the upstream regulators that mediate RP-HDM2-p53 circuits remain poorly understood. hCINAP regulates RP-HDM2-p53 pathway J Zhang et al Moreover, it is important to elucidate the mechanisms by which these upstream regulators modulate RP-HDM2-p53 pathways.
When this work was in submission, Lu and colleagues showed that both overexpression and knockdown of RPS14 could activate p53. 8 Our study here obtained similar results. RPS14 may function through different mechanisms in activating p53 as follows: When RPS14 is overexpressed, RPS14 directly binds to HDM2 and inhibits HDM2-mediated p53 polyubiquitination and degradation, therefore increases p53 stability and activity. When RPS14 is knocked down by RNAi, deficiency of RPS14 triggers ribosomal stress and results in the release of other ribosome proteins such as RPL11. The released RPL11 will bind to HDM2 and inhibit HDM2-mediated p53 ubiquitination and thus activate p53. This speculation is supported by the work reported by Lu's group and Ebert's group. 8, 31 More importantly, we have demonstrated that hCINAP is a novel regulator of the RP14-HDM2-p53 pathway and acts by regulating the interaction between RPS14 and HDM2. RPS14 stabilized and activated p53 by binding to HDM2 and inhibiting HDM2-mediated p53 polyubiquitination and degradation (Figure 2) . Moreover, hCINAP inhibited this process by downregulating the interaction of RPS14 with HDM2.
Suzuki and colleagues showed that protein interacting with carboxyl terminus-1 (PICT1) can regulate the MDM2-p53 pathway. PICT1 binds to and retains RPL11 in the nucleolus, preventing RPL11 from inhibiting MDM2 in the nucleoplasm and thereby regulating p53 activity. 38 It is reported that NEDDylation of RPL11 is required for its correct localization and stability and that deNEDDylation of RPL11 increases p53 stabilization. 19 Unlike RPL11, which is both ubiquitinated and NEDDylated, 19 we found that RPS14 was specifically modified with NEDD8 and that hCINAP inhibited NEDDylation by recruiting the deNEDDylase NEDP1. As for RPL11, NEDDylation of RPS14 was needed for its stability and correct subcellular localization. This study thus provides additional evidence for the role of NEDDylation in controlling the localization and stability of RPs and p53 signaling. Our work and Sunqvist et al.'s study 19 demonstrate that regulation of RPs' modification affect the RP-MDM2 interactions and further affect their ability in activation of p53.
It is also noteworthy that although overexpression of hCINAP or NEDP1 inhibits RPS14 NEDDylation, the reduction of RPS14 NEDDylation causes no impairment of ribosome biogenesis (Supplementary Figure S6) . This is consistent with previous report that NEDP1 expression reduced the levels of endogenous RPL11 but showed no significant changes in ribosome profiling. 18 All these observations indicate that hCINAP overexpression regulates p53 activity is through regulating RPS14-HDM2 interaction but not via impairing ribosome biogenesis.
A model for the mechanism by which hCINAP regulates the interaction between RPS14 and HDM2 is illustrated in Figure 6e . Overexpression of hCINAP inhibits RPS14 NEDDylation and leads to incorrect localization and instability of RPS14, thus attenuating the interaction between RPS14 and HDM2. The resulting increase in free HDM2 stimulates p53 polyubiquitination and degradation. Depletion of hCINAP promotes the correct localization and stability of RPS14 and enhances the interaction between RPS14 and HDM2, inhibiting HDM2-mediated p53 degradation. Taken together, our findings define hCINAP as a new upstream regulator of RP deNEDDylation and characterize a mechanism for the fine-tuning of p53 activity by hCINAP. To the best of our knowledge, hCINAP is the first protein shown to regulate the RPS14-HDM2-p53 pathway. Our results also suggest that hCINAP may have important roles in tumorigenesis and may be a potential anticancer drug target.
MATERIALS AND METHODS
Plasmids and cell culture
The pRK-FLAG-hCINAP (wild-type and mutants), pcDNA3.0-3FLAG-hCINAP, pRK-HA-RPS14, pcDNA3.0-3FLAG-NEDP1 and pEF1-His-NEDD8 expression plasmids were constructed in-house and verified by DNA sequencing. pCMV-Myc-HDM2 and its truncation constructs were kindly provided by Dr Jian Wang (State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing, China).
HEK 293T, HeLa and HCT116 cells (gifts from Prof Jun Gu, Peking University) were grown in Iscove's modified Dulbecco's medium (Gibco, Carlsbad, CA, USA) containing 10% fetal calf serum at 37 1C in a 5% CO 2 incubator.
Antibodies and reagents
Commercial antibodies were as follows: monoclonal anti-FLAG M2 and anti-HA HA-7 (Sigma, St Louis, MO, USA); anti-Myc, anti-His, anti-human MDM2 (SMP14) and anti-b-actin (MBL, Nagoya, Japan); anti-p53 (Cell Signaling, Danvers, MA, USA); and IRDye 800 CW secondary antibodies (LI-COR Biosciences, Lincoln, NE, USA). Rabbit polyclonal anti-hCINAP was described previously. 25 The proteasome inhibitor MG132 and protein synthesis inhibitor cycloheximide were purchased from Calbiochem (Darmstadt, Germany).
Transfection, immunoprecipitation and immunoblotting
Cells were transfected with the indicated plasmids using MegaTran 1.0 transfection reagent (Origene, Rockville, MD, USA) following the manufacturer's instructions. Cells were harvested at 48 h post-transfection and lysed in buffer containing 50 mM Tris-HCl (pH 8.0), 1.0% Nonidet P-40, 1 mM EDTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin and 1 mg/ml pepstatin. The supernatant was incubated with antibodies overnight at 4 1C. Protein G-Sepharose was added and samples were incubated for 4 h. Sepharose beads were washed three times with lysis buffer, and precipitated proteins were fractionated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to nitrocellulose membranes (GE Healthcare, Shanghai, China). Membranes were probed with primary and secondary antibodies as indicated.
In vitro pull-down assay Recombinant GST (glutathione S-transferase)-fused RPS14 and His-tagged hCINAP proteins were expressed and purified from Escherichia coli BL21(DE3). GST pull-down assays were carried out by incubating GST-RPS14 immobilized on glutathione-Sepharose resin (BD Biosciences, San Jose, CA, USA) with His-hCINAP at 4 1C for 3 h. His pull-down assays were performed similarly by incubating nickel resin À associated recombinant His-hCINAP with GST-RPS14 protein at 4 1C for 3 h. Beads were washed to remove unbound proteins, and bound proteins were eluted, separated by SDS-PAGE and analyzed by immunoblotting.
Luciferase reporter assay HCT116 cells were transfected with the firefly luciferase reporter plasmid pG13-Luc containing a generic p53 response element, Renilla luciferase reporter plasmid pRL-CMV (from Prof Jun Gu, Peking University, Peking, China) and other plasmids as indicated. After 24 h, cells were lysed and measured for firefly and Renilla luciferase activity using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Renilla luciferase expression in transfected cells was used to correct for variation in transfection efficiency.
In vivo NEDDylation and ubiquitination assays HCT116 cells were seeded on 10-cm tissue culture plates and transfected with corresponding plasmids. After 48 h, cells were scraped into 10 ml cold phosphate-buffered saline. Cells were divided for direct immunoblot analysis (10%) and in vivo NEDDylation or ubiquitination assays (90%) as described. 39 Briefly, cell pellets were lysed in buffer containing 6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 0.01 M Tris-HCl (pH 8.0), 5 mM imidazole and 10 mM b-mercaptoethanol and incubated with Ni þ -NTA beads (Qiagen, Shanghai, China) at room temperature for 4 h. Beads were washed once with 750 ml wash buffer 1 (6 M guanidinium-HCl; 0.1 M Na 2 HPO 4 /NaH 2 PO 4 ; 0.01 M Tris-HCl, pH 8.0; 10 mM b-mercaptoethanol), once with 750 ml wash buffer 2 (8 M urea; 0.1 M Na 2 HPO 4 /NaH 2 PO 4 ; 0.01 M Tris-HCl, pH 8.0; 10 mM b-mercaptoethanol) and twice with 750 ml wash buffer 3 (8 M urea; 0.1 M Na 2 HPO 4 /NaH 2 PO 4 ; 0.01 M Tris-HCl, pH 6.3; 10 mM b-mercaptoethanol; 0.2% Triton X-100). After the last wash, His 6 -tagged NEDDylated or ubiquitinated products were eluted by incubating the beads in 40 ml of 500 mM imidazole, 0.15 M Tris-HCl (pH 6.7), 30% glycerol, 0.72 M b-mercaptoethanol and 5% SDS for 20 min at room temperature, and eluted proteins were analyzed by immunoblotting.
Immunofluorescence analysis
Transfected HeLa cells were cultured for 48 h on glass coverslips. Cells were fixed with 3.7% paraformaldehyde for 20 min at room temperature, permeabilized with 0.3% (v/v) Triton X-100 for 10 min on ice and blocked with 3% bovine serum albumin in 0.5% Tween-20 for 20 min at room temperature. Cells were incubated with primary antibodies at 4 1C overnight, washed and incubated with fluorescently labeled secondary antibodies for 1 h at 37 1C. Fluorescence microscopy was performed by using a confocal laser scanning microscope (Leica TCS SP5, Leica Microsysteme Vertrieb GmbH, Wetzlar, Germany). All images were captured and processed under identical conditions with constant parameters (including scan speed and excitation and emission wavelengths) using Leica confocal software (Leica Microsysteme Vertrieb GmbH).
